DXCM · 10-Q · 2026Q3 · Full report

Operating Expense Trends

DEXCOM INC · 2026-10-29 · Importance 28 · Surprise 22

Nine-month selling, general and administrative expense increased $114.5 million, or approximately 12%, to $1,084.0 million from $969.5 million. The increase included $47.9 million in advertising and marketing, $22.6 million in facilities-related costs, and $20.8 million in compensation and related costs. Third-quarter SG&A increased $44.2 million to $375.6 million, including $20.7 million in advertising and marketing, $11.1 million in facilities-related costs, and $6.9 million in third-party and consulting fees. Nine-month research and development expense was $459.9 million, up $9.0 million, and was described as relatively consistent due to project-spending timing.

Key facts

• Nine-month 2026 selling, general and administrative expense was $1,084.0 million, compared with $969.5 million in the first nine months of 2025, an increase of $114.5 million. source
• Nine-month 2026 selling, general and administrative expense increased by $47.9 million in advertising and marketing, $22.6 million in facilities-related costs, and $20.8 million in compensation and related costs. source
• Third-quarter 2026 selling, general and administrative expense was $375.6 million, compared with $331.4 million in the third quarter of 2025, an increase of $44.2 million. source
• Third-quarter 2026 selling, general and administrative expense increased by $20.7 million in advertising and marketing costs, $11.1 million in facilities-related costs, and $6.9 million in third-party and consulting fees. source
• Nine-month 2026 research and development expense was $459.9 million, compared with $450.9 million in the first nine months of 2025, an increase of $9.0 million. source
• Third-quarter 2026 research and development expense was $161.6 million, compared with $157.5 million in the third quarter of 2025, an increase of $4.1 million. source